Studies published in medical journals indicate that semaglutide may ultimately contribute to this condition
The American Diabetes Association (ADA) guidelines recommend GLP-1 receptor agonists as preferred agents for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or indicators of high cardiovascular risk, or for those requiring additional glucose-lowering beyond metformin
These are not exclusive recommendations
Caron Treatment Centers, a long-standing NAATP member, has received national attention for its innovative use of GLP-1 medications such as Zepbound and Ozempic to help reduce cravings for alcohol and illicit drugs
According to FDA-approved labeling and clinical trial data, the following side effects occur most commonly: Gastrointestinal Effects: Nausea (affecting 1544% of patients, with higher rates at Wegovy doses) [3] [4] Diarrhea (reported in 830% of patients) Vomiting (524% incidence) Constipation (occurring in 324% of patients) Abdominal pain (520% of patients) These gastrointestinal symptoms typically emerge during dose escalation and often diminish with continued therapy as physiological adaptation occurs
They require a thorough evaluation and prescription from a licensed healthcare provider to ensure they are safe and appropriate for you